News Summary: Human Genome accepts Glaxo’s deal

Published



ROADBLOCK REMOVED: Human Genome Sciences drops its opposition to being acquired by longtime partner U.K. drugmaker GlaxoSmithKline, thanks to GSK’s higher offer.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.